Rallybio Announces Preliminary Phase 1 Multiple Ascending Do

-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing ---- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis ---- Company Announces Extension of Runway to 3Q 2025 As Part of Po...

Related Keywords

New Haven , Connecticut , United States , Eric Watsky , Hannah Deresiewicz , Jorge Gaeta , Twitter , Stern Investor Relations Inc , Linkedin , Company Announces Extension Of Runway , Program Lead For Rallybio , Exchange Commission , Rallybio Corporation Nasdaq , Term Development , Results Demonstrated , Mean Reduction , Low Volume Oncea Week Subcutaneous , Differentiated Therapeutic , Generalized Myasthenia , Announces Extension , Webcast Today , Rallybio Corporation , Term Development Plans , Stephen Uden , Chief Executive Officer , Technology Incubation Program , Quarterly Report , Investor Relations ,